JPH0543442A - Skin cosmetic - Google Patents
Skin cosmeticInfo
- Publication number
- JPH0543442A JPH0543442A JP20443091A JP20443091A JPH0543442A JP H0543442 A JPH0543442 A JP H0543442A JP 20443091 A JP20443091 A JP 20443091A JP 20443091 A JP20443091 A JP 20443091A JP H0543442 A JPH0543442 A JP H0543442A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- bfgf
- growth factor
- active ingredient
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 22
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 29
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 6
- 229920001184 polypeptide Polymers 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 27
- 230000000694 effects Effects 0.000 abstract description 17
- 206010042496 Sunburn Diseases 0.000 abstract description 11
- 230000037303 wrinkles Effects 0.000 abstract description 9
- 241000283690 Bos taurus Species 0.000 abstract description 6
- 239000003102 growth factor Substances 0.000 abstract description 4
- 230000006798 recombination Effects 0.000 abstract description 4
- 206010062767 Hypophysitis Diseases 0.000 abstract description 3
- 238000005215 recombination Methods 0.000 abstract description 3
- 238000007788 roughening Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 abstract 2
- 230000003328 fibroblastic effect Effects 0.000 abstract 2
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- -1 antiseptics Substances 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008311 hydrophilic ointment Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 229920003051 synthetic elastomer Polymers 0.000 description 2
- 239000005061 synthetic rubber Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100030009 Azurocidin Human genes 0.000 description 1
- 101710154607 Azurocidin Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010064489 Corneal exfoliation Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 229940021231 clearskin Drugs 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、美肌効果に優れた皮膚
化粧料に関する。さらに詳しくは、塩基性線維芽細胞増
殖因子(bFGF)を配合した日焼けによる肌あれを改
善し、皮膚の小ジワを改善する美肌効果に優れた新規な
皮膚化粧料に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a skin cosmetic having an excellent skin beautifying effect. More specifically, the present invention relates to a novel skin cosmetic containing a basic fibroblast growth factor (bFGF), which improves skin roughness caused by sunburn and improves fine wrinkles on the skin, and which has an excellent skin-beautifying effect.
【0002】[0002]
【従来の技術】皮膚は他の臓器と異なって、外界の影
響、すなわち日光、温度、湿度などの物理的因子、また
は洗剤などの化学的因子の影響を受けやすい。その中で
も特に日光に含まれる紫外線の皮膚に及ぼす悪影響は深
刻である。すなわち、長時間紫外線に曝され日焼けを起
すことにより皮膚が傷つき、炎症を引き起こし、皮膚は
脆弱化して水疱変化をきたすに至る。このような状態が
繰り返されると、皮下組織のコラーゲン線維が破壊さ
れ、肌あれ、小ジワの発生などの皮膚の老化が促進され
ることになる。2. Description of the Related Art Unlike other organs, the skin is susceptible to external influences, that is, physical factors such as sunlight, temperature and humidity, or chemical factors such as detergents. Among them, the adverse effect of ultraviolet rays contained in sunlight on the skin is particularly serious. That is, when the skin is exposed to ultraviolet rays for a long time to cause sunburn, the skin is damaged, inflammation is caused, and the skin is weakened and blisters are changed. When such a state is repeated, collagen fibers in the subcutaneous tissue are destroyed, and aging of the skin such as rough skin and wrinkles is promoted.
【0003】このような、人間の皮膚に紅斑などの炎症
を惹き起す波長は、約280〜320nmの中波光線
(U.V.B波長域)であることが知られている。It is known that the wavelength that causes inflammation such as erythema on human skin is a medium-wave ray (UV wavelength range) of about 280 to 320 nm.
【0004】従って、日焼け防止を目的とした化粧品は
一般に、U.V.B波長域の紫外線を選択的に吸収する
化合物と、特に紅斑を惹起するとされている308nm
に極大吸収値を有する化合物、例えば、サリチル酸やパ
ラアミノ安息香酸およびそのエステル類、およびケイ皮
酸誘導体などを配合することが知られている。Therefore, cosmetics intended to prevent sunburn generally have a U.S.P. V. A compound that selectively absorbs ultraviolet rays in the B wavelength range and 308 nm which is said to cause erythema in particular
It is known that a compound having a maximum absorption value, for example, salicylic acid, para-aminobenzoic acid and its esters, and a cinnamic acid derivative are compounded.
【0005】しかしながら、従来知られているこれらの
日焼け防止化粧品は、前述したように、主としてU.
V.B波長域の紫外線を吸収することにより日焼けを防
止するものであるが、日焼け防止の効果は必ずしも充分
なものとはいい難く、日焼けによる炎症を効果的に防止
する外用剤としては全く効能を示さないばかりでなく、
サリチル酸のように、皮膚に対する副作用が取り沙汰さ
れるなどの問題点もある。However, these conventionally known sunscreen cosmetics are mainly U.S. Pat.
V. Although it protects against sunburn by absorbing ultraviolet rays in the B wavelength range, the effect of preventing sunburn is not always sufficient, and it is completely effective as an external preparation that effectively prevents inflammation due to sunburn. Not only
Like salicylic acid, it also has problems such as side effects on the skin.
【0006】一方、肌あれを防止する化粧料として各種
の薬剤が使用されているが、日焼けによる炎症を伴った
重い症状の肌あれを有効に改善し、さらに皮膚の老化現
象の一つであるあれや小ジワなどを改善する美肌効果に
優れた化粧料はまだ見いだされていない。[0006] On the other hand, various chemicals are used as cosmetics for preventing skin roughening, but they are effective in improving the rough skin roughening accompanied by inflammation due to sunburn and are one of the skin aging phenomena. No cosmetics have been found that have excellent skin-beautifying effects for improving such problems such as wrinkles and fine lines.
【0007】[0007]
【発明が解決しようとする課題】したがって、本発明の
目的は、日焼けによる肌あれを改善し、小ジワなどの皮
膚の老化現象を防止するための美肌効果に優れた皮膚化
粧料を提供することにある。SUMMARY OF THE INVENTION Therefore, an object of the present invention is to provide a skin cosmetic having an excellent skin beautiful effect for improving skin roughness caused by sunburn and preventing skin aging such as fine lines. It is in.
【0008】[0008]
【課題を解決するための手段】本発明者らは、前記目的
を達成するために鋭意研究を重ねてきた。[Means for Solving the Problems] The inventors of the present invention have conducted extensive studies to achieve the above object.
【0009】その結果、アミノ酸配列として Phe−Phe−Leu−Arg−Ile−His−P
ro−Asp−Gly−Arg−Val−Asp−Gl
y−Val−Arg−Glu−Lys−Ser−Asp
−Pro で示されるポリペプチドを含むbFGFが、日焼けによ
って炎症をともなうような肌あれを改善するとともに、
小ジワなどの皮膚の老化防止効果があることを見い出し
本発明を完成した。As a result, as an amino acid sequence, Phe-Phe-Leu-Arg-Ile-His-P
ro-Asp-Gly-Arg-Val-Asp-Gl
y-Val-Arg-Glu-Lys-Ser-Asp
-BFGF containing the polypeptide represented by Pro improves the skin roughness accompanied by inflammation due to sunburn,
The present invention has been completed by discovering that it has an antiaging effect on skin such as fine wrinkles.
【0010】bFGFは、1974年にGospoda
rowiczにより、ウシの脳下垂体より発見された塩
基性のペプチド性細胞成長因子であり、〔D.Gosp
odarowicz;ネイチャー(Nature)24
9:123(1974)〕、市販のものとしては例え
ば、フナコシ薬品株式会社から販売されているウシ脳由
来のbFGF(商品名:bFGF(b))、ウシ下垂体
由来のbFGF(商品名:BASIC FIBROBL
AST GROWTH FACTOR)などが本発明に
使用できる。当初、bFGFはBALB /C 3T3細胞の
増殖刺激因子として分離されたが、その後、血管内皮細
胞を含むほとんどすべての中胚葉由来細胞に対して活性
を持つことが明らかにされた。BFGF was introduced in 1974 by Gospoda.
is a basic peptide growth factor found in bovine pituitary gland by Rowicz [D. Gosp
odarowicz; Nature 24
9: 123 (1974)], as commercially available products, for example, bovine brain-derived bFGF (trade name: bFGF (b)), bovine pituitary-derived bFGF (trade name: BASIC) sold by Funakoshi Yakuhin Co., Ltd. FIBROBL
AST GROWTH FACTOR) and the like can be used in the present invention. Initially, bFGF was isolated as a growth stimulator of B ALB / C 3T3 cells, but was subsequently shown to have activity on almost all mesodermally-derived cells including vascular endothelial cells.
【0011】これまでにbFGFは、抗潰瘍剤やとこず
れ改善剤としての利用が検討されているが、本発明のよ
うにbFGFを皮膚化粧料に配合してその有用性を研究
した例は全くない。The use of bFGF as an anti-ulcer agent and an agent for improving stinging has been studied so far, but there has been no study of its usefulness by incorporating bFGF into skin cosmetics as in the present invention. ..
【0012】即ち、本発明は塩基性線維芽細胞増殖因子
(以下単にbFGFということがある)を有効成分とす
ることを特徴とする新規な皮膚化粧料を提供するもので
ある。[0012] That is, the present invention provides a novel skin cosmetic characterized by containing a basic fibroblast growth factor (hereinafter sometimes simply referred to as bFGF) as an active ingredient.
【0013】本発明において使用しうるbFGFは、 Phe−Phe−Leu−Arg−Ile−His−P
ro−Asp−Gly−Arg−Val−Asp−Gl
y−Val−Arg−Glu−Lys−Ser−Asp
−Pro で示されるアミノ酸配列を有するポリペプチドを含んで
いるものであり、天然のものはもちろん、ペプチド合成
法、遺伝子組替え技術による量産化によって得たものも
使用可能である。The bFGF which can be used in the present invention is Phe-Phe-Leu-Arg-Ile-His-P.
ro-Asp-Gly-Arg-Val-Asp-Gl
y-Val-Arg-Glu-Lys-Ser-Asp
It includes a polypeptide having an amino acid sequence represented by -Pro, and naturally occurring ones as well as those obtained by mass production by peptide synthesis methods and gene recombination techniques can be used.
【0014】上記アミノ酸配列において、Pheはフェ
ニルアラニンを、Leuはロイシンを、Argはアルギ
ニンを、Ileはイソロイシンを、Hisはヒスチジン
を、Proはプロリンを、Aspはアスパラギン酸を、
Glyはグリシンを、Valはバリンを、Gluはグル
タミン酸を、Lysはリジンを、そしてSerはセリン
をそれぞれ意味する略号である。In the above amino acid sequence, Phe is phenylalanine, Leu is leucine, Arg is arginine, Ile is isoleucine, His is histidine, Pro is proline and Asp is aspartic acid.
Gly means glycine, Val means valine, Glu means glutamic acid, Lys means lysine, and Ser means serine.
【0015】本発明に使用できる天然のものとしては、
「プロシーデングス・オブ・ザ・ナショナル・アカデミ
ー・オブ・ザ・ユナイテッド・ステーツ・オブ・アメリ
カ(Proc.Natl.Acad.Sci.US
A)」,第82巻 第6507−6511頁(1985
年)などに記載されたもの、例えばウシの脳下垂体、
脳、網膜、黄体、副腎、腎、胎盤、前立腺、胸腺などか
ら分離された分子量15〜18KDa、pI 9.6、
アミノ酸146個のヘパリン結合性のタンパクが挙げら
れ、ペプチド合成法のものとしては、Phe−Phe−
Leu−Arg−Ile−His−Pro−Asp−G
ly−Arg−Val−Asp−Gly−Val−Ar
g−Glu−Lys−Ser−Asp−Proのアミノ
酸配列を有するペプチド、遺伝子組み替え技術によるも
のとしては、特開平2−193号公報に記載されたもの
が含まれ、分子量は特に制限されないが、天然物と同じ
アミノ酸系列を含むタンパク、少なくとも1個のbFG
F構成アミノ酸が欠損したものおよび少なくとも1個の
bFGF構成アミノ酸が別のアミノ酸で置換されたも
の、例えばシステインがセリンに置換されたムテインな
どが挙げられる。The natural substances that can be used in the present invention include:
“Procedures of the National Academy of the United States of America (Proc. Natl. Acad. Sci. US
A) ", vol. 82, pages 6507-6511 (1985).
, Etc., such as bovine pituitary gland,
Molecular weight 15-18 KDa, pI 9.6 isolated from brain, retina, luteum, adrenal gland, kidney, placenta, prostate, thymus, etc.
A heparin-binding protein having 146 amino acids can be mentioned. As a method for peptide synthesis, Phe-Phe-
Leu-Arg-Ile-His-Pro-Asp-G
ly-Arg-Val-Asp-Gly-Val-Ar
Peptides having the amino acid sequence of g-Glu-Lys-Ser-Asp-Pro and those produced by the gene recombination technique include those described in JP-A-2-193, and the molecular weight is not particularly limited, Protein containing at least one amino acid sequence, at least one bFG
Examples thereof include those lacking the F constituent amino acids and those in which at least one bFGF constituent amino acid has been replaced with another amino acid, such as muteins in which cysteine has been replaced with serine.
【0016】本発明の皮膚化粧料は、医薬部外品、化粧
品を含むものであり、その剤型としては外用可能な種々
の形態、例えばクリーム、軟膏、乳剤、ローション、乳
液、エッセンス、パック、ゲルなどの公知の形態に製剤
化して使用でき、その基剤も皮膚施用上許容し得る任意
の液状および固形状の原料を幅広く使用できる。The skin cosmetic of the present invention includes quasi-drugs and cosmetics, and its dosage forms include various externally applicable forms such as cream, ointment, emulsion, lotion, emulsion, essence, pack, and the like. It can be used by formulating it into a known form such as gel, and its base material can be widely used in any liquid and solid raw materials which are acceptable for skin application.
【0017】その際、必要に応じて防腐剤、香料、安定
剤、着色剤、紫外線吸収剤、酸化防止剤、保湿剤、増粘
剤など種々の添加剤を加えることもできる。At this time, various additives such as antiseptics, fragrances, stabilizers, colorants, ultraviolet absorbers, antioxidants, humectants and thickeners can be added, if necessary.
【0018】本発明の皮膚化粧料の有効成分であるbF
GFの配合量は適用部位、症状の度合、剤型などによっ
て適宜変更してよいが、通常200〜2,000,00
0単位程度、好ましくは2,000〜1,000,00
0単位程度を製剤中に配合する。BF which is an active ingredient of the skin cosmetic composition of the present invention
The amount of GF may be appropriately changed depending on the application site, the degree of symptoms, the dosage form, etc., but it is usually 200 to 2,000,000.
0 unit or so, preferably 2,000 to 1,000,000
About 0 unit is included in the formulation.
【0019】尚、ここではチミジン取込み量を2倍に上
げる活性を1単位と定義する。Here, the activity that doubles the thymidine uptake amount is defined as 1 unit.
【0020】この有効成分は単独使用のほか、皮膚化粧
料に通常用いられる有効成分と併用することもでき、例
えば、セファランチン、ビタミンE、ビタミンEニコチ
ネート、ニコチン酸、ニコチン酸アミド、ニコチン酸ベ
ンジル、ショウキョウチンキ、トウガラシチンキなどの
末梢血管拡張剤、カンフル、メントールなどの清涼剤、
ヒノキチオール、塩基ベンザルコニウム、ウンデシレン
酸などの抗菌剤、塩化リゾチーム、グリチルリチン、ア
ラントインなどの消炎剤、アスコルビン酸、アルブチ
ン、コウジ酸などの色白剤、センブリエキス、ニンニク
エキス、ニンジンエキス、オウゴンエキス、ローズマリ
ーエキス、アロエエキス、胎盤抽出液、肝臓抽出物など
の動物・植物由来の各種抽出物などが適宣選択して自由
に使用することができる。This active ingredient can be used alone or in combination with an active ingredient usually used in skin cosmetics. For example, cepharanthin, vitamin E, vitamin E nicotinate, nicotinic acid, nicotinic acid amide, benzyl nicotinate, Peripheral vasodilators such as ginger tincture and capsicum tincture, cooling agents such as camphor and menthol,
Antibacterial agents such as hinokitiol, base benzalkonium, and undecylenic acid, anti-inflammatory agents such as lysozyme chloride, glycyrrhizin, and allantoin, whitening agents such as ascorbic acid, arbutin, and kojic acid, assemblage extract, garlic extract, carrot extract, sardine extract, rose. Various extracts derived from animals or plants such as marie extract, aloe extract, placenta extract and liver extract can be appropriately selected and used freely.
【0021】次に、本発明の皮膚化粧料の実施例並びに
その効果の試験例を挙げるが、これらは本発明を何ら限
定するものではない。Next, examples of skin cosmetics of the present invention and test examples of their effects will be shown, but these do not limit the present invention at all.
【0022】[0022]
【実施例】実施例1 クリーム ウシ脳由来のbFGF 20,000単位 (重量%) A モノステアリン酸 2.0 ポリエチレングリコール(40.E.O.) 自己乳化型モノステアリン酸グリセリン 5.0 ステアリン酸 5.0 ベヘニルアルコール 1.0 流動パラフィン 10.0 トリオクタン酸グリセリル 10.0 B グリセリン 5.0 エルパラベン 0.1 精製水 適 量 Aに属する成分を加熱溶解する。別に、Bに属する成分
を加熱溶解する。AにBを添加して有効成分であるbF
GFを加えて攪拌、乳化後、冷却してクリームを製造し
た。EXAMPLES Example 1 Cream Bovine brain-derived bFGF 20,000 units (wt%) A Monostearic acid 2.0 Polyethylene glycol (40.EO) Self-emulsifying glyceryl monostearate 5.0 Stearic acid 5.0 Behenyl alcohol 1.0 Liquid paraffin 10.0 Glyceryl trioctanoate 10.0 B Glycerin 5.0 Elparaben 0.1 Purified water Appropriate amount The components belonging to A are dissolved by heating. Separately, the components belonging to B are melted by heating. BF which is an active ingredient by adding B to A
GF was added, and the mixture was stirred, emulsified, and cooled to produce a cream.
【0023】実施例2 乳液 bFGFムテイン 10,000単位 (2個のシステインをセリンに置換したムテイン) (重量%) A モノステアリン酸ポリオキシエチレンソルビタン (20.E.O.) 1.0 モノステアリン酸ポリオキシエチレンソルビット (60.E.O.) 0.5 親油型モノステアリン酸グリセリン 1.0 ステアリン酸 0.5 ベヘニルアルコール 0.5 アボガド油 4.0 トリオクタン酸グリセリル 4.0 B 1,3−ブチレングリコール 5.0 メチルパラベン 0.2 精製水 適 量 Aに属する成分を加熱溶解する。別に、Bに属する成分
を加熱溶解する。AにBを添加して有効成分であるbF
GFムテインを加えて攪拌、乳化後、冷却して乳液を製
造した。Example 2 Emulsion bFGF mutein 10,000 units (mutein in which two cysteines were replaced by serine) (% by weight) A Polyoxyethylenesorbitan monostearate (20.EO.) 1.0 Monostearin Acid polyoxyethylene sorbit (60.EO) 0.5 Lipophilic glyceryl monostearate 1.0 Stearic acid 0.5 Behenyl alcohol 0.5 Avocado oil 4.0 Glyceryl trioctanoate 4.0 B 1,3 -Butylene glycol 5.0 Methylparaben 0.2 Purified water Appropriate amount The components belonging to A are dissolved by heating. Separately, the components belonging to B are melted by heating. BF which is an active ingredient by adding B to A
GF mutein was added, stirred, emulsified, and cooled to prepare an emulsion.
【0024】実施例3 化粧水 bFGF活性を有する合成ペプチド 500,000単位 (重量%) ポリオキシエチレン硬化ヒマシ油(60.E.O.) 8.0 エタノール 15.0 エチルパラベン 0.1 グリセリン 2.0 1,3−ブチレングリコール 4.0 エデト酸二ナトリウム 0.01 精製水 適 量 上記の各成分を混合、均一に攪拌、溶解し化粧水を製造
した。Example 3 Lotion Lotion Synthetic peptide having bFGF activity 500,000 units (% by weight) Polyoxyethylene hydrogenated castor oil (60.EO.) 8.0 Ethanol 15.0 Ethylparaben 0.1 Glycerin 2 0.0 1,3-butylene glycol 4.0 Disodium edetate 0.01 Purified water Appropriate amount The above components were mixed, uniformly stirred and dissolved to produce a lotion.
【0025】実施例4 クリームパック bFGF(遺伝子組み替えにより得たもの) 20,000単位 〔商品名:RECOMBINANT FIBROBLASTGROWTH FACTOR,BASIC フナコシ薬品株式会社販売〕 (重量%) A ビーガム 5.0 スクワラン 2.0 プロピレングリコール 5.0 ビタミンB12 0.05 精製水 適 量 B 酸化亜鉛 10.0 C エタノール 5.0 Aに属する成分を混合、攪拌して膨潤させ、Bを少しず
つ加える。これにCを徐々に加え、さらにbFGFを加
えてペースト状になるまで混練しクリームパックを製造
した。Example 4 Cream pack bFGF (obtained by genetic recombination) 20,000 units [Product name: RECOMBINANT FIBROBLAST GROWTH FACTOR, BASIC, sold by Funakoshi Chemical Co., Ltd.] (% by weight) A Veegum 5.0 Squalane 2.0 Propylene Glycol 5.0 Vitamin B 12 0.05 Purified water Appropriate amount B Zinc oxide 10.0 C Ethanol 5.0 Mix components belonging to A, swell by stirring, and add B little by little. C was gradually added to this, and bFGF was further added and kneaded until a paste was formed to prepare a cream pack.
【0026】実施例5 エッセンス (重量%) bFGF 200,000単位 (2個のシステインをセリンに置換したムテイン) 1%カルボキシビニルポリマー溶液 10.0 グリセリン 20.0 ヒアルロン酸 0.5 エタノール 1.0 精製水 適 量 上記の各成分を混合、均一に攪拌、溶解しエッセンスを
製造した。Example 5 Essence (% by weight) bFGF 200,000 units (mutein in which two cysteines are replaced by serine) 1% carboxyvinyl polymer solution 10.0 glycerin 20.0 hyaluronic acid 0.5 ethanol 1.0 Purified water Appropriate amount The above components were mixed, uniformly stirred and dissolved to produce an essence.
【0027】実施例6 親水性軟膏 (重量%) 天然由来のbFGF 0.01 A ポリオキシエチレンセチルエーテル 2.0 グリセリルモノステアレート 10.0 流動パラフィン 10.0 ワセリン 4.0 セタノール 5.0 B プロピレングリコール 10.0 メチルパラベン 0.1 精製水 適 量 Aに属する成分を加熱溶解する。別に、Bに属する成分
を加温溶解する。AにBを添加して有効成分であるbF
GFを加えて攪拌、乳化後、冷却して親水性軟膏を製造
した。Example 6 Hydrophilic Ointment (wt%) Naturally occurring bFGF 0.01 A Polyoxyethylene cetyl ether 2.0 Glyceryl monostearate 10.0 Liquid paraffin 10.0 Vaseline 4.0 Cetanol 5.0 B Propylene glycol 10.0 Methylparaben 0.1 Purified water Appropriate amount The components belonging to A are dissolved by heating. Separately, the components belonging to B are dissolved by heating. BF which is an active ingredient by adding B to A
After adding GF, stirring and emulsifying, cooling was performed to produce a hydrophilic ointment.
【0028】〔試験例〕 試験例1 レプリカ法による皮膚表面の観察測定 a)試験方法 紫外線照射によリレプリカスコアの1の評価になった肌
(皮溝・皮丘の消失があり、広範囲の角層の剥離が認め
られるもの)を有する50名の被検者をランダムに2群
に振り分け、第1群には実施例1で調製したクリーム
を、第2群には基剤(実施例1のクリームから有効成分
bFGFを除いたもの)を0.3±0.1g、1日2
回、12時間おきに塗布し、塗布開始時と塗布後1週間
の皮膚の表面状態をレプリカに採り、その結果を実体顕
微鏡(20倍)にて観察した。[Test Example] Test Example 1 Observation and Measurement of Skin Surface by Replica Method a) Test Method A skin having a re-replica score of 1 by ultraviolet irradiation (there is a disappearance of skin crevices / hills and a wide range of skin). Fifty subjects having corneal exfoliation are randomly distributed into two groups, the cream prepared in Example 1 is used in the first group, and the base (Example 1) is used in the second group. 0.3 ± 0.1 g of the cream (excluding the active ingredient bFGF) from 2
It was applied once every 12 hours, and the surface condition of the skin at the start of application and one week after the application was taken as a replica, and the result was observed with a stereoscopic microscope (20 times).
【0029】レプリカは、熊谷らの方法〔SCCJ.V
ol 19,No.1(1985)p.9〜19〕に準
拠して皮膚表面に速乾性のシリコン系合成ゴムを使用し
てネガレプリカを採り、これにポリサルファイド系合成
ゴムを充填してポジレプリカを採った。The replica is obtained by the method of Kumagai et al. [SCCJ. V
ol 19, No. 1 (1985) p. 9 to 19], a negative replica was taken on the skin surface using a quick-drying silicone synthetic rubber, and a polysulphide synthetic rubber was filled in the negative replica to obtain a positive replica.
【0030】b)試験結果 次の表1のとおりであった。B) Test Results The results are shown in Table 1 below.
【0031】[0031]
【表1】 [Table 1]
【0032】〈皮膚表面状態の評価分類〉 評価 1:皮溝・皮丘の消失、広範囲の角層の剥離が認
められる。<Evaluation Classification of Skin Surface Condition> Evaluation 1: Disappearance of skin groove / concrete and wide exfoliation of stratum corneum are recognized.
【0033】2:皮溝・皮丘が不明瞭であり、角層の剥
離が認められる。2: The sulcus and crust are unclear, and peeling of the stratum corneum is observed.
【0034】3:皮溝・皮丘は認めるが、平坦であり一
方向に流れている。3: Although there are some pits and ridges, they are flat and flow in one direction.
【0035】4:皮溝・皮丘が明瞭である。4: Defects and cuticles are clear.
【0036】5:皮溝・皮丘が鮮明で網目状に整ってい
る。5: Clear skin grooves and cuts arranged in a mesh pattern.
【0037】以上のように、本発明の有効成分であるb
FGFは、傷んだ肌の改善効果に優れていることが明ら
かである。As described above, b which is the active ingredient of the present invention
It is clear that FGF has an excellent effect of improving damaged skin.
【0038】試験例2 ハーフフェイス法によるシワ
改善効果試験 a)試験方法 本発明のエッセンス(実施例5)を、30名の女性(3
5〜55才)に朝晩の1日2回、顔面に連続塗布し、3
ヶ月後に小ジワの改善の程度を調べた。顔面の塗布は、
ハーフフェイス法で左右に行い、一方には本発明のエッ
センスを、他の一方側にはコントロールとしてbFGF
を含まないもの(基剤のみ)を塗布し評価した。Test Example 2 Wrinkle Improvement Effect Test by Half Face Method a) Test Method The essence of the present invention (Example 5) was tested by 30 women (3
5 to 55 years old), apply to face continuously twice a day in the morning and evening.
After a month, the degree of improvement of small wrinkles was examined. Apply on face
The half-face method is performed on the left and right sides, and the essence of the present invention is used for one side and bFGF for the other side as a control.
What did not contain (base only) was applied and evaluated.
【0039】b)試験結果 エッセンス使用前に対する小ジワの改善度を判定した結
果、本発明のエッセンスに明らかな小ジワ改善効果が認
められた。また、連続使用による皮膚異常は何ら認めら
れなかった。結果を表2に示す。B) Test Results As a result of judging the degree of improvement of small wrinkles before the use of essence, the essence of the present invention was found to have a clear effect of improving small wrinkles. In addition, no skin abnormality was observed after continuous use. The results are shown in Table 2.
【0040】[0040]
【表2】 [Table 2]
【0041】[0041]
【発明の効果】本発明によれば、塩基性線維芽細胞増殖
因子(bFGF)を有効成分とする新規な皮膚化粧料が
提供され、皮膚に適用することにより、日焼けによる傷
んだ肌の改善が極めて効果的に達成でき、小ジワなどの
皮膚の老化を防止することができる。また、皮膚に対す
る安全性も高い有用な皮膚化粧料である。EFFECTS OF THE INVENTION According to the present invention, a novel skin cosmetic containing a basic fibroblast growth factor (bFGF) as an active ingredient is provided, and by applying it to the skin, it is possible to improve the skin damaged by sunburn. It can be achieved very effectively and can prevent skin aging such as fine lines. In addition, it is a useful skin cosmetic that is highly safe to the skin.
Claims (2)
を有効成分とすることを特徴とする皮膚化粧料。1. Basic fibroblast growth factor (bFGF)
A skin cosmetic comprising the following as an active ingredient.
ro−Asp−Gly−Arg−Val−Asp−Gl
y−Val−Arg−Glu−Lys−Ser−Asp
−Pro を含むポリペプチドである請求項1記載の皮膚化粧料。2. bFGF has an amino acid sequence of Phe-Phe-Leu-Arg-Ile-His-P.
ro-Asp-Gly-Arg-Val-Asp-Gl
y-Val-Arg-Glu-Lys-Ser-Asp
The skin cosmetic according to claim 1, which is a polypeptide containing -Pro.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20443091A JPH0543442A (en) | 1991-08-14 | 1991-08-14 | Skin cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20443091A JPH0543442A (en) | 1991-08-14 | 1991-08-14 | Skin cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0543442A true JPH0543442A (en) | 1993-02-23 |
Family
ID=16490410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP20443091A Pending JPH0543442A (en) | 1991-08-14 | 1991-08-14 | Skin cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0543442A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994004184A3 (en) * | 1992-08-12 | 1994-06-23 | Bays Brown Dermatologics Inc | Method of decreasing cutaneous senescence |
| WO1996005850A1 (en) * | 1994-08-18 | 1996-02-29 | Research Development Foundation | Cytokine regulation of cellular senescence |
| US6143723A (en) * | 1996-05-20 | 2000-11-07 | Ramaiah; Abburi | Pigmentory agent |
| JP2002363081A (en) * | 2001-06-06 | 2002-12-18 | Nof Corp | Hyaluronic acid production enhancer and use thereof |
| JP2005060314A (en) * | 2003-08-13 | 2005-03-10 | Masao Tanihara | Cosmetic |
| KR20070000005A (en) * | 2005-06-24 | 2007-01-02 | 주식회사 아디포랩 | Cosmetic composition containing fibroblast growth factor |
| WO2007032029A1 (en) * | 2005-09-13 | 2007-03-22 | Abburi Ramaiah | Agonist peptides of basic fibroblast growth factor (bfgf) and the method of reduction of wrinkle on skin, darkening of hair and acceleration of wound healing |
| JP2008100981A (en) * | 2006-10-17 | 2008-05-01 | Engelhard Lyon Sas | USE OF SUBSTANCE FOR PROTECTING FGF-2 OR FGF-beta GROWTH FACTOR |
| WO2009119073A1 (en) | 2008-03-28 | 2009-10-01 | 北海道公立大学法人札幌医科大学 | Agent for treating skin aging and scars |
| JP2009235004A (en) * | 2008-03-27 | 2009-10-15 | J Hewitt Kk | Method for promoting cellular tissue increase and method for ameliorating skin problem, and kit used in these methods |
| CN108721136A (en) * | 2018-07-04 | 2018-11-02 | 广州领衔生物科技有限公司 | Maintenance gel and its preparation method and application |
-
1991
- 1991-08-14 JP JP20443091A patent/JPH0543442A/en active Pending
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994004184A3 (en) * | 1992-08-12 | 1994-06-23 | Bays Brown Dermatologics Inc | Method of decreasing cutaneous senescence |
| WO1996005850A1 (en) * | 1994-08-18 | 1996-02-29 | Research Development Foundation | Cytokine regulation of cellular senescence |
| US6143723A (en) * | 1996-05-20 | 2000-11-07 | Ramaiah; Abburi | Pigmentory agent |
| JP2002363081A (en) * | 2001-06-06 | 2002-12-18 | Nof Corp | Hyaluronic acid production enhancer and use thereof |
| JP2005060314A (en) * | 2003-08-13 | 2005-03-10 | Masao Tanihara | Cosmetic |
| KR20070000005A (en) * | 2005-06-24 | 2007-01-02 | 주식회사 아디포랩 | Cosmetic composition containing fibroblast growth factor |
| US8314065B2 (en) | 2005-09-13 | 2012-11-20 | Abburi Ramaiah | Method of reduction of wrinkles on skin or acceleration of wound healing by applying peptides related to basic fibroblast growth factor (bFGF) |
| WO2007032029A1 (en) * | 2005-09-13 | 2007-03-22 | Abburi Ramaiah | Agonist peptides of basic fibroblast growth factor (bfgf) and the method of reduction of wrinkle on skin, darkening of hair and acceleration of wound healing |
| JP2008100981A (en) * | 2006-10-17 | 2008-05-01 | Engelhard Lyon Sas | USE OF SUBSTANCE FOR PROTECTING FGF-2 OR FGF-beta GROWTH FACTOR |
| JP2009235004A (en) * | 2008-03-27 | 2009-10-15 | J Hewitt Kk | Method for promoting cellular tissue increase and method for ameliorating skin problem, and kit used in these methods |
| WO2009119073A1 (en) | 2008-03-28 | 2009-10-01 | 北海道公立大学法人札幌医科大学 | Agent for treating skin aging and scars |
| US8518878B2 (en) | 2008-03-28 | 2013-08-27 | Labo Juversa Co., Ltd. | Method for treating skin aging by administration of bFGF |
| EP2263683A4 (en) * | 2008-03-28 | 2013-11-13 | Labo Juversa Co Ltd | Agent for treating skin aging and scars |
| JP5553284B2 (en) * | 2008-03-28 | 2014-07-16 | 株式会社ラボ・ジュヴェルサ | Skin aging and scar treatment |
| US9023792B2 (en) | 2008-03-28 | 2015-05-05 | Labo Juversa Co., Ltd. | Method for treating keloid and hypertrophic scars by administration of bFGF |
| CN108721136A (en) * | 2018-07-04 | 2018-11-02 | 广州领衔生物科技有限公司 | Maintenance gel and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4707354A (en) | Mature skin treatment and protectant compositions and methods of using same | |
| CN103096980B (en) | Skin Anti-Aging Treatment | |
| KR101007637B1 (en) | Skin metabolism bioactive agent | |
| KR20140043727A (en) | Peptides useful in the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions | |
| JP3389071B2 (en) | Cosmetics | |
| CN101790536A (en) | Novel compounds, their use in cosmetic and cosmeceutical applications and compositions comprising them | |
| JP4088436B2 (en) | Skin preparation | |
| JPH09291011A (en) | Composition suitable for eternal use | |
| KR20060007040A (en) | Psoriasis composition and method | |
| JPH06279227A (en) | Dermatic external preparation and cosmetic | |
| JPH0543442A (en) | Skin cosmetic | |
| KR100377397B1 (en) | Skin care composition containing retinol and epidermal growth factor | |
| TWI675849B (en) | Use of compound or cosmetically acceptable salt thereof for wrinkle reduction | |
| JPH09183718A (en) | Composition suitable for external application | |
| JP4088497B2 (en) | Cosmetics | |
| JP3172753B2 (en) | Biological hyaluronic acid synthesis promoter | |
| KR20010102559A (en) | Composition for cosmetic and dermatological skin care | |
| JPH0532533A (en) | Cosmetics | |
| JPH01275511A (en) | External drug for skin | |
| JP2011042613A (en) | Anti-aging skin care preparation and anti-aging cosmetic | |
| JPH0543424A (en) | External agent for use in hair | |
| JP2004131401A (en) | Skin cosmetic | |
| KR102281606B1 (en) | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex | |
| KR102382002B1 (en) | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex and natural ingredients | |
| US20060293227A1 (en) | Cosmetic compositions and methods using transforming growth factor-beta mimics |